PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31221747-5 2019 Instead, GST P1-1 sequesters and inactivates cisplatin with the aid of 2 solvent-accessible cysteines, resulting in protein subunits cross-linking, while maintaining its GSH-conjugation activity. Cisplatin 45-54 glutathione S-transferase pi 1 Homo sapiens 9-17 31263672-0 2019 Transcriptional Activation of Gstp1 by MEK/ERK Signaling Confers Chemo-Resistance to Cisplatin in Lung Cancer Stem Cells. Cisplatin 85-94 glutathione S-transferase pi 1 Homo sapiens 30-35 31249357-0 2019 GSTM1, GSTT1 and GSTP1 Ile105Val polymorphisms in outcomes of head and neck squamous cell carcinoma patients treated with cisplatin chemoradiation. Cisplatin 122-131 glutathione S-transferase pi 1 Homo sapiens 17-22 31249357-2 2019 Glutathione S-transferases (GSTs) participate in CDDP excretion from cells, and genes encoding GSTs, GSTM1, GSTT1and GSTP1, are polymorphic in humans. Cisplatin 49-53 glutathione S-transferase pi 1 Homo sapiens 117-122 31249357-10 2019 Our findings provide preliminary evidence that inherited abnormalities in CDDP metabolism, related to GSTT1 and GSTP1 Ile105Val polymorphisms, alter outcomes of HNSCC patients treated with CDDP and RT. Cisplatin 74-78 glutathione S-transferase pi 1 Homo sapiens 112-117 31263672-8 2019 Further, transcriptional activation of Gstp1 expression by MEK/ERK signaling underlies cisplatin resistance in lung CSC cells. Cisplatin 87-96 glutathione S-transferase pi 1 Homo sapiens 39-44 30341887-2 2018 This study aimed to undertake a literature review and meta-analysis of GST gene polymorphisms, including GSTT1, GSTM1, and GSTP1 IIe105Val, and the treatment response to cisplatin-based chemotherapy in patients with NSCLC. Cisplatin 170-179 glutathione S-transferase pi 1 Homo sapiens 123-128 30499150-10 2019 Viability of GSTP1 knockdown cells treated with cisplatin was lower than that of control cells (P < .01). Cisplatin 48-57 glutathione S-transferase pi 1 Homo sapiens 13-18 30499150-11 2019 Moreover, the frequency of early and late apoptosis in GSTP1 knockdown cells was markedly increased over that of control cells by cisplatin exposure (P < .01). Cisplatin 130-139 glutathione S-transferase pi 1 Homo sapiens 55-60 30361796-11 2019 CONCLUSION: The GSTP1 c.313A>G variant may increase the risk of low-frequency HL in pediatric oncology patients treated with cisplatin or carboplatin chemotherapy. Cisplatin 128-137 glutathione S-transferase pi 1 Homo sapiens 16-21 30870506-3 2019 GSTP1 c.313A>G genotype was recently described as a predictor of vomiting related to high-dose cisplatin. Cisplatin 95-104 glutathione S-transferase pi 1 Homo sapiens 0-5 30341887-6 2018 RESULTS Twenty-three published studies were identified that showed that both the null GSTM1 and the GG genotype of GSTP1 IIe105Val were associated with improved treatment response to cisplatin-based chemotherapy (GSTT1 present/null: OR=1.328; 95% CI, 1.074-1.643) (GSTP1 GG + AG vs. AA: OR=0.596; 95% CI, 0.468-0.759). Cisplatin 183-192 glutathione S-transferase pi 1 Homo sapiens 115-120 30341887-6 2018 RESULTS Twenty-three published studies were identified that showed that both the null GSTM1 and the GG genotype of GSTP1 IIe105Val were associated with improved treatment response to cisplatin-based chemotherapy (GSTT1 present/null: OR=1.328; 95% CI, 1.074-1.643) (GSTP1 GG + AG vs. AA: OR=0.596; 95% CI, 0.468-0.759). Cisplatin 183-192 glutathione S-transferase pi 1 Homo sapiens 265-270 30341887-8 2018 CONCLUSIONS Meta-analysis showed that the GG genotype of GSTP1 IIe105Val and the null GSTM1 genotype were associated with an improved treatment response to cisplatin-based chemotherapy in patients with NSCLC, especially in East-Asian patients. Cisplatin 156-165 glutathione S-transferase pi 1 Homo sapiens 57-62 27729156-8 2016 RESULTS: According to univariate analyses, male gender, co-treatment with aminoglycosides and mutant genotype of GSTP1 rs1695 were significantly related with cisplatin ototoxicity. Cisplatin 158-167 glutathione S-transferase pi 1 Homo sapiens 113-118 29328427-0 2018 miR-133b reverses cisplatin resistance by targeting GSTP1 in cisplatin-resistant lung cancer cells. Cisplatin 18-27 glutathione S-transferase pi 1 Homo sapiens 52-57 29328427-0 2018 miR-133b reverses cisplatin resistance by targeting GSTP1 in cisplatin-resistant lung cancer cells. Cisplatin 61-70 glutathione S-transferase pi 1 Homo sapiens 52-57 29328427-3 2018 Reverse transcription-quantitative polymerase chain reaction and western blot assays of the cisplatin-resistant cell lines A549/DPP and H1299/DDP displayed the reduced expression of miR-133b and increased expression of glutathione-S-transferase P1 (GSTP1) in the resistant cells compared with the respective parental cell lines A549 and H1299. Cisplatin 92-101 glutathione S-transferase pi 1 Homo sapiens 219-247 29328427-3 2018 Reverse transcription-quantitative polymerase chain reaction and western blot assays of the cisplatin-resistant cell lines A549/DPP and H1299/DDP displayed the reduced expression of miR-133b and increased expression of glutathione-S-transferase P1 (GSTP1) in the resistant cells compared with the respective parental cell lines A549 and H1299. Cisplatin 92-101 glutathione S-transferase pi 1 Homo sapiens 249-254 29328427-7 2018 In conclusion, the present study findings provide the insights that miR-133b reduces cisplatin resistance and its overexpression contributes to the suppression of the malignant growth and aggressiveness of cisplatin-resistant NSCLC cells by targeting GSTP1. Cisplatin 206-215 glutathione S-transferase pi 1 Homo sapiens 251-256 27544755-8 2016 It inhibited nuclear factor erythroid 2-related factor 2 and glutathione S-transferase P in cisplatin-resistant HNC cells, resulting in increased ROS accumulation in HNC cells, an effect that could be blocked by the antioxidant N-acetyl-L-cysteine. Cisplatin 92-101 glutathione S-transferase pi 1 Homo sapiens 61-88 26823821-1 2015 We conducted a study to investigate the association between the clinical outcome and GSTP1 Ile105Val and XRCC1 Arg194Trp, Arg280His and Arg399Gln gene polymorphisms in advanced NSCLC patients with cisplatin-based chemotherapy. Cisplatin 197-206 glutathione S-transferase pi 1 Homo sapiens 85-90 26033426-0 2015 Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients. Cisplatin 20-29 glutathione S-transferase pi 1 Homo sapiens 89-94 26033426-1 2015 INTRODUCTION: This study is to evaluate the association of polymorphisms of glutathione S-transferase P1 (GSTP1), copper-transporting P-type adenosine triphosphatase A (ATP7A) and X-ray repair cross-complementing group 1 (XRCC1) with the efficacy and toxicity of cisplatin-based treatment in advanced non-small cell lung cancer (NSCLC) patients. Cisplatin 263-272 glutathione S-transferase pi 1 Homo sapiens 76-104 26033426-1 2015 INTRODUCTION: This study is to evaluate the association of polymorphisms of glutathione S-transferase P1 (GSTP1), copper-transporting P-type adenosine triphosphatase A (ATP7A) and X-ray repair cross-complementing group 1 (XRCC1) with the efficacy and toxicity of cisplatin-based treatment in advanced non-small cell lung cancer (NSCLC) patients. Cisplatin 263-272 glutathione S-transferase pi 1 Homo sapiens 106-111 26033426-9 2015 CONCLUSIONS: Advanced NSCLC patients with AA genotype of GSTP1 would obtain better curative effect followed with more risk of anemia when treated by cisplatin-based chemotherapy. Cisplatin 149-158 glutathione S-transferase pi 1 Homo sapiens 57-62 25010864-4 2014 METHODS: Glutathione S-transferase P1 was stably deleted in A2780 and expression significantly reduced in cisplatin-resistant A2780DPP cells using Mission shRNA constructs, and MTT assays used to compare chemosensitivity to chemotherapy drugs used to treat ovarian cancer. Cisplatin 106-115 glutathione S-transferase pi 1 Homo sapiens 9-37 26345972-5 2015 The results of our study suggest that the GSTP1 rs1695 and XRCC1 rs25487 polymorphisms might affect the clinical outcome of patients with advanced NSCLC receiving cisplatin-based chemotherapy. Cisplatin 163-172 glutathione S-transferase pi 1 Homo sapiens 42-47 26097600-0 2015 Association of GSTP1 and XRCC1 gene polymorphisms with clinical outcome of advanced non-small cell lung cancer patients with cisplatin-based chemotherapy. Cisplatin 125-134 glutathione S-transferase pi 1 Homo sapiens 15-20 26097600-1 2015 We investigated the association between the clinical outcome and GSTP1 and XRCC1 gene polymorphisms in advanced NSCLC patients with cisplatin-based chemotherapy. Cisplatin 132-141 glutathione S-transferase pi 1 Homo sapiens 65-70 26097600-8 2015 GSTP1 A313G and XRCC1 Arg399Gln gene polymorphisms might influence the response to cisplatin-based chemotherapy and affect the clinical outcome of advanced NSCLC. Cisplatin 83-92 glutathione S-transferase pi 1 Homo sapiens 0-5 26028097-0 2015 Association of GSTP1 and RRM1 Polymorphisms with the Response and Toxicity of Gemcitabine-cisplatin Combination Chemotherapy in Chinese Patients with Non-small Cell Lung Cancer. Cisplatin 90-99 glutathione S-transferase pi 1 Homo sapiens 15-20 25010864-7 2014 RESULTS: Glutathione S-transferase P1 knockdown selectively influenced cisplatin and carboplatin chemosensitivity (2.3- and 4.83-fold change in IC50, respectively). Cisplatin 71-80 glutathione S-transferase pi 1 Homo sapiens 9-37 25010864-10 2014 CONCLUSIONS: Glutathione S-transferase P1 has an important role in cisplatin and carboplatin metabolism in ovarian cancer cells. Cisplatin 67-76 glutathione S-transferase pi 1 Homo sapiens 13-41 23106910-6 2012 Ethanol upregulated GSTP1 and ALDH2 mRNAs, whereas cisplatin upregulated GSTP1 in HEK293 cells. Cisplatin 51-60 glutathione S-transferase pi 1 Homo sapiens 73-78 23842854-10 2013 In conclusion, the GSTP1 expression is a good predictor of prognosis, and it may be closely related to the chemotherapeutic efficacy of 5-FU plus cisplatin in ESCC patients. Cisplatin 146-155 glutathione S-transferase pi 1 Homo sapiens 19-24 23106910-7 2012 SET-chromatin binding revealed SET interaction with ALDH2 and GSTP1 promoters, specifically via SET NAP domain; ethanol and cisplatin abolished SET binding. Cisplatin 124-133 glutathione S-transferase pi 1 Homo sapiens 62-67 22749944-3 2012 Glutathione S-transferase P1 (GSTP1) has been reported to contribute to cisplatin resistance in many studies. Cisplatin 72-81 glutathione S-transferase pi 1 Homo sapiens 0-28 23330092-0 2012 Expression of genes of glutathione transferase isoforms GSTP1-1, GSTA4-4, and GSTK1-1 in tumor cells during the formation of drug resistance to cisplatin. Cisplatin 144-153 glutathione S-transferase pi 1 Homo sapiens 56-63 22749944-3 2012 Glutathione S-transferase P1 (GSTP1) has been reported to contribute to cisplatin resistance in many studies. Cisplatin 72-81 glutathione S-transferase pi 1 Homo sapiens 30-35 22749944-7 2012 This study aims to determine whether deregulated miRNAs can sensitize human lung adenocarcinoma cells to cisplatin by targeting GSTP1. Cisplatin 105-114 glutathione S-transferase pi 1 Homo sapiens 128-133 22749944-11 2012 In conclusion, our data demonstrated that miR-513a-3p can sensitize human lung adenocarcinoma cells to cisplatin by targeting GSTP1. Cisplatin 103-112 glutathione S-transferase pi 1 Homo sapiens 126-131 22068640-0 2012 Targeting GSTP1-1 induces JNK activation and leads to apoptosis in cisplatin-sensitive and -resistant human osteosarcoma cell lines. Cisplatin 67-76 glutathione S-transferase pi 1 Homo sapiens 10-17 21851097-2 2011 Here we used novel strategies to target microsomal glutathione transferase 1 (MGST1) and glutathione transferase pi (GSTP) that are often overexpressed in tumors and confer resistance against a number of cytostatic drugs, including cisplatin and doxorubicin (DOX). Cisplatin 232-241 glutathione S-transferase pi 1 Homo sapiens 117-121 20654585-3 2010 Using two malignant glioma cell lines, MGR1 and MGR3, the ability of PKCalpha-phosphorylated GSTP1 to catalyze the conjugation of cisplatin to glutathione was assessed and correlated with cisplatin sensitivity and cisplatin-induced DNA interstrand cross-links and apoptosis of the cells. Cisplatin 130-139 glutathione S-transferase pi 1 Homo sapiens 93-98 21286668-1 2011 The aim of this study was to investigate the relationship between the ERCC1-C8092A, ERCC1-C19007T and GSTP1-A105G genetic polymorphisms and the curative effect of cisplatin-based chemotherapy in advanced esophageal carcinoma. Cisplatin 163-172 glutathione S-transferase pi 1 Homo sapiens 102-107 21133646-0 2011 Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy. Cisplatin 171-180 glutathione S-transferase pi 1 Homo sapiens 66-94 21133646-1 2011 The objective of this study was to determine whether the expressions of the excision cross-complementing (ERCC1), thymidylate synthase (TS) and glutathione S-transferase P1 (GSTP1) are predictive of clinical outcomes in advanced gastric cancer (AGC) patients receiving treatment with adjuvant 5-fluorouracil (5-FU) and cisplatin (FP) chemotherapy. Cisplatin 319-328 glutathione S-transferase pi 1 Homo sapiens 174-179 20654585-0 2010 Serine phosphorylation of glutathione S-transferase P1 (GSTP1) by PKCalpha enhances GSTP1-dependent cisplatin metabolism and resistance in human glioma cells. Cisplatin 100-109 glutathione S-transferase pi 1 Homo sapiens 26-54 20654585-0 2010 Serine phosphorylation of glutathione S-transferase P1 (GSTP1) by PKCalpha enhances GSTP1-dependent cisplatin metabolism and resistance in human glioma cells. Cisplatin 100-109 glutathione S-transferase pi 1 Homo sapiens 56-61 20654585-0 2010 Serine phosphorylation of glutathione S-transferase P1 (GSTP1) by PKCalpha enhances GSTP1-dependent cisplatin metabolism and resistance in human glioma cells. Cisplatin 100-109 glutathione S-transferase pi 1 Homo sapiens 84-89 20654585-2 2010 In this study, we investigated the contribution of this post-translational modification of GSTP1 to tumor cisplatin resistance. Cisplatin 106-115 glutathione S-transferase pi 1 Homo sapiens 91-96 20654585-3 2010 Using two malignant glioma cell lines, MGR1 and MGR3, the ability of PKCalpha-phosphorylated GSTP1 to catalyze the conjugation of cisplatin to glutathione was assessed and correlated with cisplatin sensitivity and cisplatin-induced DNA interstrand cross-links and apoptosis of the cells. Cisplatin 188-197 glutathione S-transferase pi 1 Homo sapiens 93-98 20654585-3 2010 Using two malignant glioma cell lines, MGR1 and MGR3, the ability of PKCalpha-phosphorylated GSTP1 to catalyze the conjugation of cisplatin to glutathione was assessed and correlated with cisplatin sensitivity and cisplatin-induced DNA interstrand cross-links and apoptosis of the cells. Cisplatin 188-197 glutathione S-transferase pi 1 Homo sapiens 93-98 20654585-4 2010 The results showed PKCalpha activation and associated phosphorylation of GSTP1 to correlate significantly with increased glutathionylplatinum formation, decreased DNA interstrand cross-link formation and increased cisplatin resistance. Cisplatin 214-223 glutathione S-transferase pi 1 Homo sapiens 73-78 20654585-6 2010 In both cell lines, siRNA-mediated GSTP1 or PKCalpha transcriptional suppression similarly decreased cisplatin IC(50) and was associated with decreased intracellular levels of glutathionylplatinum metabolite. Cisplatin 101-110 glutathione S-transferase pi 1 Homo sapiens 35-40 20654585-7 2010 Combined inhibition/transcriptional suppression of both PKCalpha and GSTP1 was synergistic in enhancing cisplatin sensitivity. Cisplatin 104-113 glutathione S-transferase pi 1 Homo sapiens 69-74 20654585-8 2010 Although, cisplatin-induced apoptosis was associated with the translocation of Bax to mitochondria, release of cytochrome c and caspase-3/7 activation, the levels of relocalized Bax and cytochrome c were significantly greater following GSTP1 knockdown. Cisplatin 10-19 glutathione S-transferase pi 1 Homo sapiens 236-241 20654585-9 2010 These results support a mechanism of cisplatin resistance mediated by the PKCalpha-dependent serine phosphorylation of GSTP1 and its associated increased cisplatin metabolism, and suggest the potential of simultaneous targeting of GSTP1 and PKCalpha to improve the efficacy of cisplatin therapy. Cisplatin 37-46 glutathione S-transferase pi 1 Homo sapiens 119-124 20654585-9 2010 These results support a mechanism of cisplatin resistance mediated by the PKCalpha-dependent serine phosphorylation of GSTP1 and its associated increased cisplatin metabolism, and suggest the potential of simultaneous targeting of GSTP1 and PKCalpha to improve the efficacy of cisplatin therapy. Cisplatin 37-46 glutathione S-transferase pi 1 Homo sapiens 231-236 20654585-9 2010 These results support a mechanism of cisplatin resistance mediated by the PKCalpha-dependent serine phosphorylation of GSTP1 and its associated increased cisplatin metabolism, and suggest the potential of simultaneous targeting of GSTP1 and PKCalpha to improve the efficacy of cisplatin therapy. Cisplatin 154-163 glutathione S-transferase pi 1 Homo sapiens 119-124 20654585-9 2010 These results support a mechanism of cisplatin resistance mediated by the PKCalpha-dependent serine phosphorylation of GSTP1 and its associated increased cisplatin metabolism, and suggest the potential of simultaneous targeting of GSTP1 and PKCalpha to improve the efficacy of cisplatin therapy. Cisplatin 154-163 glutathione S-transferase pi 1 Homo sapiens 119-124 19396019-0 2009 GSTP1 determines cis-platinum cytotoxicity in gastric adenocarcinoma MGC803 cells: regulation by promoter methylation and extracellular regulated kinase signaling. Cisplatin 17-29 glutathione S-transferase pi 1 Homo sapiens 0-5 18852128-1 2008 Cells expressing elevated levels of allelic variants of human glutathione S-transferase P1 (GSTP1) and/or efflux transporters, MRP1 or MRP2, were used to evaluate the role of GSTP1-1 in cisplatin resistance. Cisplatin 186-195 glutathione S-transferase pi 1 Homo sapiens 175-182 18852128-0 2008 Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin. Cisplatin 73-82 glutathione S-transferase pi 1 Homo sapiens 8-36 18852128-2 2008 These studies revealed that GSTP1-1 confers low-level resistance (1.4- to 1.7-fold) to cisplatin-induced cytotoxicity in MCF7 cells. Cisplatin 87-96 glutathione S-transferase pi 1 Homo sapiens 28-35 18852128-4 2008 To understand the mechanism by which variants of GSTP1-1 confer resistance to cisplatin, their relative abilities to catalyze conjugation of cisplatin with glutathione were examined. Cisplatin 78-87 glutathione S-transferase pi 1 Homo sapiens 49-56 18852128-4 2008 To understand the mechanism by which variants of GSTP1-1 confer resistance to cisplatin, their relative abilities to catalyze conjugation of cisplatin with glutathione were examined. Cisplatin 141-150 glutathione S-transferase pi 1 Homo sapiens 49-56 18852128-6 2008 Although these data are consistent with the idea that very low level resistance to cisplatin may be conferred by GSTP1-1-mediated cisplatin/glutathione conjugation, two observations indicate that such catalysis plays a minor role in the protection from cisplatin toxicity. Cisplatin 83-92 glutathione S-transferase pi 1 Homo sapiens 113-120 18852128-6 2008 Although these data are consistent with the idea that very low level resistance to cisplatin may be conferred by GSTP1-1-mediated cisplatin/glutathione conjugation, two observations indicate that such catalysis plays a minor role in the protection from cisplatin toxicity. Cisplatin 130-139 glutathione S-transferase pi 1 Homo sapiens 113-120 18852128-6 2008 Although these data are consistent with the idea that very low level resistance to cisplatin may be conferred by GSTP1-1-mediated cisplatin/glutathione conjugation, two observations indicate that such catalysis plays a minor role in the protection from cisplatin toxicity. Cisplatin 130-139 glutathione S-transferase pi 1 Homo sapiens 113-120 18852128-9 2008 We conclude that high-level cisplatin resistance attributed to GSTP1-1 in other studies is not likely due to catalysis of cisplatin conjugation but rather must be explained by other mechanisms, which may include GSTP1-mediated modulation of signaling pathways. Cisplatin 28-37 glutathione S-transferase pi 1 Homo sapiens 63-70 18852128-9 2008 We conclude that high-level cisplatin resistance attributed to GSTP1-1 in other studies is not likely due to catalysis of cisplatin conjugation but rather must be explained by other mechanisms, which may include GSTP1-mediated modulation of signaling pathways. Cisplatin 28-37 glutathione S-transferase pi 1 Homo sapiens 63-68 18852128-9 2008 We conclude that high-level cisplatin resistance attributed to GSTP1-1 in other studies is not likely due to catalysis of cisplatin conjugation but rather must be explained by other mechanisms, which may include GSTP1-mediated modulation of signaling pathways. Cisplatin 122-131 glutathione S-transferase pi 1 Homo sapiens 63-68 17513610-6 2007 Our results showed that GSTP1 expression was up-regulated in osteosarcoma cells when they were treated with doxorubicin or cisplatin. Cisplatin 123-132 glutathione S-transferase pi 1 Homo sapiens 24-29 18701490-0 2008 Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma. Cisplatin 48-57 glutathione S-transferase pi 1 Homo sapiens 11-39 18701490-2 2008 By using a series of CDDP-resistant variants, which were established from the U-2OS and Saos-2 human osteosarcoma cell lines, we found that CDDP resistance was mainly associated with the increase of both the intracellular level and enzymatic activity of glutathione S-transferase P1 (GSTP1). Cisplatin 21-25 glutathione S-transferase pi 1 Homo sapiens 254-282 18701490-2 2008 By using a series of CDDP-resistant variants, which were established from the U-2OS and Saos-2 human osteosarcoma cell lines, we found that CDDP resistance was mainly associated with the increase of both the intracellular level and enzymatic activity of glutathione S-transferase P1 (GSTP1). Cisplatin 21-25 glutathione S-transferase pi 1 Homo sapiens 284-289 18701490-2 2008 By using a series of CDDP-resistant variants, which were established from the U-2OS and Saos-2 human osteosarcoma cell lines, we found that CDDP resistance was mainly associated with the increase of both the intracellular level and enzymatic activity of glutathione S-transferase P1 (GSTP1). Cisplatin 140-144 glutathione S-transferase pi 1 Homo sapiens 254-282 18701490-2 2008 By using a series of CDDP-resistant variants, which were established from the U-2OS and Saos-2 human osteosarcoma cell lines, we found that CDDP resistance was mainly associated with the increase of both the intracellular level and enzymatic activity of glutathione S-transferase P1 (GSTP1). Cisplatin 140-144 glutathione S-transferase pi 1 Homo sapiens 284-289 18701490-8 2008 In conclusion, our findings show that GSTP1 has a relevant effect for both CDDP resistance and clinical outcome of high-grade osteosarcoma and that targeting GSTP1 with NBDHEX may be considered a promising new therapeutic possibility for osteosarcoma patients who fail to respond to conventional chemotherapy. Cisplatin 75-79 glutathione S-transferase pi 1 Homo sapiens 38-43 17593093-1 2007 AIM: Glutathione-S-transferase P1 (GSTP1) detoxifies a wide range of endogenous and exogenous carcinogens and anticancer agents such as cisplatin and doxorubicin. Cisplatin 136-145 glutathione S-transferase pi 1 Homo sapiens 5-33 17593093-1 2007 AIM: Glutathione-S-transferase P1 (GSTP1) detoxifies a wide range of endogenous and exogenous carcinogens and anticancer agents such as cisplatin and doxorubicin. Cisplatin 136-145 glutathione S-transferase pi 1 Homo sapiens 35-40 17593093-2 2007 The aim of this study was to examine the association between GSTP1 polymorphism and both urothelial cancer susceptibility and adverse events of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy in Japanese urothelial cancer patients. Cisplatin 194-203 glutathione S-transferase pi 1 Homo sapiens 61-66 17513610-9 2007 The cytotoxicity assay also showed that GSTP1 suppression caused a 2.5-fold increase in cell growth inhibition resulting from doxorubicin and cisplatin treatments [the IC(50)s are approximately 0.16 micromol/L (doxorubicin) and 1.8 micromol/L (cisplatin) for parental HOS versus 0.06 micromol/L (doxorubicin) and 0.75 micromol/L (cisplatin) for GSTP1-silenced HOS]. Cisplatin 142-151 glutathione S-transferase pi 1 Homo sapiens 40-45 17513610-9 2007 The cytotoxicity assay also showed that GSTP1 suppression caused a 2.5-fold increase in cell growth inhibition resulting from doxorubicin and cisplatin treatments [the IC(50)s are approximately 0.16 micromol/L (doxorubicin) and 1.8 micromol/L (cisplatin) for parental HOS versus 0.06 micromol/L (doxorubicin) and 0.75 micromol/L (cisplatin) for GSTP1-silenced HOS]. Cisplatin 142-151 glutathione S-transferase pi 1 Homo sapiens 345-350 17513610-9 2007 The cytotoxicity assay also showed that GSTP1 suppression caused a 2.5-fold increase in cell growth inhibition resulting from doxorubicin and cisplatin treatments [the IC(50)s are approximately 0.16 micromol/L (doxorubicin) and 1.8 micromol/L (cisplatin) for parental HOS versus 0.06 micromol/L (doxorubicin) and 0.75 micromol/L (cisplatin) for GSTP1-silenced HOS]. Cisplatin 244-253 glutathione S-transferase pi 1 Homo sapiens 40-45 17513610-9 2007 The cytotoxicity assay also showed that GSTP1 suppression caused a 2.5-fold increase in cell growth inhibition resulting from doxorubicin and cisplatin treatments [the IC(50)s are approximately 0.16 micromol/L (doxorubicin) and 1.8 micromol/L (cisplatin) for parental HOS versus 0.06 micromol/L (doxorubicin) and 0.75 micromol/L (cisplatin) for GSTP1-silenced HOS]. Cisplatin 244-253 glutathione S-transferase pi 1 Homo sapiens 40-45 17513610-10 2007 Moreover, GSTP1 suppression decreased the activation of extracellular signal-regulated kinase 1/2, which is induced by cisplatin and doxorubicin. Cisplatin 119-128 glutathione S-transferase pi 1 Homo sapiens 10-15 17513610-11 2007 Taken together, these findings show that GSTP1 contributes to doxorubicin and cisplatin resistance in osteosarcoma, which may be mediated in part by the activation of extracellular signal-regulated kinase 1/2. Cisplatin 78-87 glutathione S-transferase pi 1 Homo sapiens 41-46 17513610-7 2007 GSTP1 overexpression in SAOS-2 osteosarcoma cells caused the cells to be more resistant to doxorubicin and cisplatin. Cisplatin 107-116 glutathione S-transferase pi 1 Homo sapiens 0-5 17513610-8 2007 In contrast, GSTP1 suppression in HOS cells caused more apoptosis and extensive DNA damage in response to doxorubicin and cisplatin. Cisplatin 122-131 glutathione S-transferase pi 1 Homo sapiens 13-18 9776312-0 1998 Combined expression of multidrug resistance protein (MRP) and glutathione S-transferase P1-1 (GSTP1-1) in MCF7 cells and high level resistance to the cytotoxicities of ethacrynic acid but not oxazaphosphorines or cisplatin. Cisplatin 213-222 glutathione S-transferase pi 1 Homo sapiens 94-101 17228018-11 2007 CONCLUSION: The presence of both alleles of 105Val-GSTP1 offered protection against cisplatin-induced hearing impairment. Cisplatin 84-93 glutathione S-transferase pi 1 Homo sapiens 51-56 16317430-11 2006 Testing for TS and GSTP1 polymorphisms may allow identification of gastric cancer patients who will benefit from 5-FU/cisplatin chemotherapy, sparing others the side effects of this chemotherapy. Cisplatin 118-127 glutathione S-transferase pi 1 Homo sapiens 19-24 15254763-3 2004 We hypothesized that head and neck squamous cell carcinoma (HNSCC) might respond differently to chemotherapeutic agents, especially cisplatin (CDDP) because of the presence of GSTP1 I105V polymorphism. Cisplatin 132-141 glutathione S-transferase pi 1 Homo sapiens 176-181 15254763-3 2004 We hypothesized that head and neck squamous cell carcinoma (HNSCC) might respond differently to chemotherapeutic agents, especially cisplatin (CDDP) because of the presence of GSTP1 I105V polymorphism. Cisplatin 143-147 glutathione S-transferase pi 1 Homo sapiens 176-181 15347473-0 2004 [Killing effect of adenovirus mediated fusion gene cytosine and deaminase uracil phosphoribosyl transferase directed by glutathione S-transferase P1 promoter on cisplatin-resistant ovarian cancer cells in vitro]. Cisplatin 161-170 glutathione S-transferase pi 1 Homo sapiens 120-148 15347473-1 2004 OBJECTIVE: To construct an adenoviral vector in which the fusion gene cytosine and uracil phosphoribosyl (UPP) transferase was directed by glutathione S-transferase P1 (GSTP1) promoter, and to investigate specific killing effect of the suicide gene system on cisplatin-resistant ovarian cancer cells. Cisplatin 259-268 glutathione S-transferase pi 1 Homo sapiens 169-174 15347473-8 2004 CONCLUSION: Recombinant adenovirus carrying CD-UPP gene driven by GSTP1 promoter has a specific killing effect on cisplatin-resistant ovarian cancer cells. Cisplatin 114-123 glutathione S-transferase pi 1 Homo sapiens 66-71 11874074-8 2001 In the subgroup of patients that received cisplatin-based chemotherapy (n = 14) significantly higher GSTP1-1 (p = 0.01) concentrations were found in patients with recurrence compared with patients without recurrence. Cisplatin 42-51 glutathione S-transferase pi 1 Homo sapiens 101-108 15279901-4 2004 When we transduced the methylated oligonucleotides to A549 lung adenocarcinoma cells, methylation of the GSTP1 promoter and reduction of GSTP1 expression was induced, cell viability was reduced; however, chemoresistance against cisplatin has not clearly changed. Cisplatin 228-237 glutathione S-transferase pi 1 Homo sapiens 105-110 12805482-4 2003 Transfection of the GSTP1-1 antisense expression vector into a human cholangiocarcinoma cell line (HuCCT1) apparently decreased its intracellular GSTP1-1 concentration, and the sensitivity of transfectants to adriamycin (ADR), cisplatin, and alkylating agents such as melphalan and 4-hydroxyperoxycyclophosphamide (4-HC) was increased significantly, compared with that of mock transfectants. Cisplatin 227-236 glutathione S-transferase pi 1 Homo sapiens 20-27 7857716-1 1994 Class pi-glutathione S-transferase (GSTP-1) is one of several factors proposed to affect drug sensitivity to cisdiamminedichloroplatinum (II) (CDDP). Cisplatin 109-136 glutathione S-transferase pi 1 Homo sapiens 36-42 7857716-1 1994 Class pi-glutathione S-transferase (GSTP-1) is one of several factors proposed to affect drug sensitivity to cisdiamminedichloroplatinum (II) (CDDP). Cisplatin 143-147 glutathione S-transferase pi 1 Homo sapiens 36-42 34164774-5 2021 circ-CHI3L1.2 knockdown decreased the half-maximal inhibitory concentration (IC50) of cisplatin and the expression levels of P-glycoprotein (P-gp), multidrug-resistance protein 1 (MRP1), and glutathione-S-transferase Pi1 (GSTP1), and promoted apoptosis of cisplatin-resistant osteosarcoma cells. Cisplatin 86-95 glutathione S-transferase pi 1 Homo sapiens 191-220 21533477-5 1997 The GSTP1 cDNA transfectant KB/BSO3-pi established from KB/BSO3, and also HLE/BSO1-pi and HLE/BSO2-pi established from HLE/BSO1 and HLE/BSO2, restored cellular sensitivities to cisplatin and alkylating agents to similar levels as KB and HLE cells. Cisplatin 177-186 glutathione S-transferase pi 1 Homo sapiens 4-9 21533477-6 1997 Our present results indicate that GSTP1 levels apparently limit cellular sensitivities to cisplatin and alkylating agents, suggesting that GSTP1 is a useful diagnostic marker for drug sensitivities to these agents in human cancer cells. Cisplatin 90-99 glutathione S-transferase pi 1 Homo sapiens 34-39 21533477-6 1997 Our present results indicate that GSTP1 levels apparently limit cellular sensitivities to cisplatin and alkylating agents, suggesting that GSTP1 is a useful diagnostic marker for drug sensitivities to these agents in human cancer cells. Cisplatin 90-99 glutathione S-transferase pi 1 Homo sapiens 139-144